This was a particularly exciting finding as she is similar to many women we see with breast cancer-related lymphedema: node positive disease requiring multimodal adjuvant therapy resulting in significant weight gain leading to or exacerbating their lymphedema
Jeffrey Flier, former Dean at Harvard Medical School, writes in STAT on How Pfizer ended up passing on my GLP-1 work back in the early 90s. Flier kicks off with Despite extremely promising results, Pfizer, the major funder of the work in alliance with California Biotechnology, abandoned the effort around 1991 after mistakenly concluding that the GLP-1 therapeutic approach was not worth continuing. He states that he is not trying to take credit for the GLP-1 market, rather that the story offers valuable lessons on drug development for pharmaceutical companies, researchers, and the general public alike. The article describes the early stages of drug development and testing from 1987, with Pfizer against an injectable GLP-1 version, and a focus on a way to deliver GLP-1 via transnasal, transcutaneous, or oral administration
Methionine reduces histamine levels, improving the symptoms of chronic allergies or inflammatory conditions
Improves blood flow Supports faster recovery post-exercise Boosts stamina and sexual health Acts quickly in the body However, its low bioavailability limits its long-term effects when taken as a supplement
They are precision tools that help the body remember how to heal - naturally, intelligently, and from the inside out
Frequently Asked Questions How long does it take for copper peptides to work for hair growth
